Something I posted on "another board".... Market capture

New Post Public Reply Private Reply Replies (0) Message Board
chuckles759
1,035
Something I posted on "another board"....

Market capture is critical. Getting the word out that this drug is available either through (E)IND, compassionate use, or clinical trial is critical. I just found out this evening that one of my childhood friends has surrendered his fate to God after battling 15 years of cancer and four rounds of chemo. He has three beautiful and smart young daughters, a loving wife doing everything she can to hold it together, and a huge group of friends that are doing everything they can do to make his limited presence in this life more comfortable. He's a fighter but feels that another round of chemo will be the end. I've forwarded him NP and DrJ's info to share with his oncologist in hope that he might be a candidate for Leronlimab treatment.

I ask anyone who wishes - please pray for him - his name is Mike.

But cancer affecting millions isn't the only pestilence that Leronlimab can hopefully resolve. For just HIV, there are approx 38 million infected and about 1.7 million being added every year. If CYDY were able to touch only 10% of that it would be almost 4 million individuals whose lives would be remarkably improved. They would be able to lead more normal lives, their families and friends would be able to share in their presence on this earth leading a longer and more fruitful life.

As investors we have a moral prerogative to support and defend CytoDyn to allow them to bring Leronlimab to those most in need.

Time to double down and share the news with everyone in our circles of influence. Facebook, LinkedIn, etc - post what you can in language that your audience can understand. Dr. Yo has some wonderful videos. Some of the Proactive videos are helpful too. CytoDyn Updates on YouTube is full of informative videos.

I'm not suggesting that you convince anyone to invest in the company, but just to know that Leronlimab exists, it's on the horizon, and to ensure that it's given a fair playing field for being accessible to those in need.

So, do you know anyone with any of the following conditions that are potential indications that Leronlimab can possibly improve and extend their lives?

We can do this. Get the word out.

Again, here is a list of possible conditions that Leronlimab can help.
How many more "Gandhi" or "Einsteins" or "fill-in-the-blank-individuals" would be able to contribute to making our world a better place.


Allergies (anaphylactic shock)
Alzheimer's
Asthma
Atherosclerosis
Atopic Dermatitis
Cancer
Coeliac Disease
Chronic Fatigue Syndrome
Chronic Kidney Disease (underlying pathologies)
COPD
COVID-19 (and other coronaviruses)
Crohn's Disease
Colitis
Dermatomyositis
Diabetes (type 1 and 2)
Duchenne Muscular Dystrophy (possibly other muscular dystrophies also)
Emphysema
Fibromyalgia
Grave’s Disease
Guillain-Barre Syndrome
GVHD
Hashimoto’s Thyroiditis
Hepatitis (autoimmune)
HIV
Idiopathic Pulmonary Fibrosis
Inflammatory Bowel Disease
Influenza (severe)
Kawasaki Syndrome
Lambert-Eaton Syndrome
Lupus
Marshall’s syndrome (PFAPA)
Multiple Sclerosis
Myasthenia Gravis
Myocarditis
NASH
Neurofibromatosis
Parkinson's Disease
Pemphigus
Pneumonia
Polymyositis
Post-Myocardial Infarction Syndrome
Psoriasis
Rheumatic Fever
Rheumatoid Arthritis
Sarcoidosis
Scleroderma
Sickle Cell Disease (anti-inflammatory effect)
Sjogren’s Syndrome
Stroke
Tuberculosis
Vasculitis

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

GE HealthCare Launches Innovative Ultrasound Systems for Women

Updated Category News Views 289

GE HealthCare Unveils New Voluson Expert Series Ultrasound Systems GE HealthCare recently announced the launch of its enhanced Voluson Expert Series ultrasound systems, aiming to improve early detection and streamline exam efficiency in women's healthcare. With FDA 510(k) clearance achieved, these innovative systems—Voluson Expert 22, 20, and 18—combine...

Continue Reading
Newmont Corp: Dominating Gold Mining with Impressive Gains

Updated Category News Views 291

Newmont Corp's Standout Performance In a market filled with technology giants, Newmont Corp (NYSE: NEM) is making headlines for its remarkable performance this year. Rising an astonishing 106% year-to-date (YTD), the largest gold miner is turning ore into a sought-after treasure for investors. The stability of gold prices amid ongoing inflation concerns has positioned...

Continue Reading
Seeking Justice: Class Action Lawsuit for Fiserv, Inc. Investors

Updated Category News Views 221

Overview of the Fiserv, Inc. Class Action Investors who have experienced significant losses in Fiserv, Inc. (NYSE: FI) stock are encouraged to take action. Robbins LLP is currently leading a class action lawsuit, aimed at helping those impacted during a specific class period of the company’s troubling financial disclosures. Why Join the Class Action? This initiative is...

Continue Reading
Lepage Millwork to Acquire Custom Window Maker Fenêtres MQ

Updated Category News Views 262

Big Move in Windows: Lepage Eyes Fenêtres MQ Dust off those old window ledgers, folks, because we've got a shake-up in the custom luxury window game. Lepage Millwork, a family-run titan in the North American fenestration scene, is gearing up to take over Fenêtres MQ from the big shots over at Andersen. We're talking about an ownership shift set to seal the deal by...

Continue Reading
Probe Gold's Annual Meeting Highlights Key Voting Outcomes

Updated Category News Views 181

Key Highlights from Probe Gold's Annual General Meeting Probe Gold Inc., with its stock traded as TSX: PRB and OTCQB: PROBF, held its Annual General Meeting (AGM) where significant decisions were made that will shape the company's future. This meeting was filled with exciting developments as shareholders came together to participate in the governance of the company....

Continue Reading